Logo image of NYKD.OL

NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Price, Quote, News and Overview

OSL:NYKD - Euronext Oslo - NO0010714785 - Common Stock - Currency: NOK

2.59  +0.06 (+2.29%)

NYKD.OL Quote, Performance and Key Statistics

NYKODE THERAPEUTICS ASA

OSL:NYKD (5/6/2025, 2:53:15 PM)

2.59

+0.06 (+2.29%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.2
52 Week Low1.55
Market Cap845.76M
Shares326.55M
Float168.36M
Yearly DividendN/A
Dividend Yield40.49%
PEN/A
Fwd PEN/A
Earnings (Next)05-14 2025-05-14
IPO01-27 2020-01-27


NYKD.OL short term performance overview.The bars show the price performance of NYKD.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

NYKD.OL long term performance overview.The bars show the price performance of NYKD.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of NYKD.OL is 2.59 NOK. In the past month the price increased by 16.04%. In the past year, price decreased by -81.97%.

NYKODE THERAPEUTICS ASA / NYKD Daily stock chart

NYKD.OL Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 19.07 305.33B
1ABBV.MI ABBVIE INC 18.36 294.00B
AMG.DE AMGEN INC 13.41 131.91B
1GILD.MI GILEAD SCIENCES INC 13.7 116.36B
VX1.DE VERTEX PHARMACEUTICALS INC 1709.42 114.26B
GIS.DE GILEAD SCIENCES INC 13.22 112.29B
ARGX.BR ARGENX SE 375.03 35.04B
22UA.DE BIONTECH SE-ADR N/A 21.40B
IDP.DE BIOGEN INC 7.73 15.80B
1MRNA.MI MODERNA INC N/A 9.49B
0QF.DE MODERNA INC N/A 9.38B
BIO.DE BIOTEST AG 64.92 1.67B

About NYKD.OL

Company Profile

NYKD logo image Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

Company Info

NYKODE THERAPEUTICS ASA

Oslo Science Park, Gaustadalleen 21

Oslo OSLO NO

Employees: 179

NYKD Company Website

NYKD Investor Relations

Phone: 4722958193

NYKODE THERAPEUTICS ASA / NYKD.OL FAQ

What is the stock price of NYKODE THERAPEUTICS ASA today?

The current stock price of NYKD.OL is 2.59 NOK. The price increased by 2.29% in the last trading session.


What is the ticker symbol for NYKODE THERAPEUTICS ASA stock?

The exchange symbol of NYKODE THERAPEUTICS ASA is NYKD and it is listed on the Euronext Oslo exchange.


On which exchange is NYKD.OL stock listed?

NYKD.OL stock is listed on the Euronext Oslo exchange.


What is the price forecast or stock price prediction for NYKODE THERAPEUTICS ASA stock?

9 analysts have analysed NYKD.OL and the average price target is 5.44 NOK. This implies a price increase of 110.04% is expected in the next year compared to the current price of 2.59. Check the NYKODE THERAPEUTICS ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NYKODE THERAPEUTICS ASA worth?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 845.76M NOK. This makes NYKD.OL a Small Cap stock.


How many employees does NYKODE THERAPEUTICS ASA have?

NYKODE THERAPEUTICS ASA (NYKD.OL) currently has 179 employees.


What are the support and resistance levels for NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a support level at 2.42 and a resistance level at 2.54. Check the full technical report for a detailed analysis of NYKD.OL support and resistance levels.


Is NYKODE THERAPEUTICS ASA (NYKD.OL) expected to grow?

The Revenue of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to grow by 22.17% in the next year. Check the estimates tab for more information on the NYKD.OL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NYKODE THERAPEUTICS ASA (NYKD.OL) stock pay dividends?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 40.49%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of NYKD.OL dividend history, reliability and sustainability.


When does NYKODE THERAPEUTICS ASA (NYKD.OL) report earnings?

NYKODE THERAPEUTICS ASA (NYKD.OL) will report earnings on 2025-05-14.


What is the Price/Earnings (PE) ratio of NYKODE THERAPEUTICS ASA (NYKD.OL)?

NYKODE THERAPEUTICS ASA (NYKD.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).


NYKD.OL Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to NYKD.OL. When comparing the yearly performance of all stocks, NYKD.OL is a bad performer in the overall market: 94.74% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NYKD.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. NYKD.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NYKD.OL Financial Highlights

Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 90.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.29%
ROE -28.5%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%90.74%
Sales Q2Q%-70.9%
EPS 1Y (TTM)90.47%
Revenue 1Y (TTM)-32.72%

NYKD.OL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to NYKD.OL. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 17.8% and a revenue growth 22.17% for NYKD.OL


Ownership
Inst Owners17.19%
Ins Owners2.42%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target5.44 (110.04%)
EPS Next Y17.8%
Revenue Next Year22.17%